Peptides
SLU-PP-332
Also called SLU-PP332 · ERR agonist
SLU-PP-332 draws interest for fat loss and endurance—the “exercise mimetic” idea. Mouse studies showed exercise-like metabolic changes, but they do not show that it replaces training or produces the same results in people. Human online experiments remain uncontrolled reports.
Dosage & duration
An individual online experiment; no validated human dose or cycle identified.
Two-week public liquid-use report
Reported use · unapproved regimen- Dose
- 1,800 mcg total per day
- How often
- Reported as 3 divided daily doses
- How long
- Two-week update
Product strength and results were self-reported; the post does not specify the administration route. This is not a typical, tested or recommended regimen.
The practical difference
What “exercise mimetic” means here
Fat loss and endurance are the appeal. The supporting experiments are in cells and mice.
| Question | What researchers studied | What that does not establish |
|---|---|---|
| Endurance | Exercise-related muscle programs and mouse performance | A reliable endurance improvement in people |
| Fat loss | Energy use and fat-mass changes in mouse models | A predictable human weight-loss result |
| Replacing exercise | Selected exercise-related pathways | The full benefits of training or a safe human regimen |
Why “exercise in a pill” gets attention
The hoped-for combination is higher endurance and easier fat loss. SLU-PP-332 activates cell-energy programs studied in mice; exercise also improves skills, strength and cardiovascular fitness in ways a chemical cannot be assumed to reproduce.
Online results are hard to interpret
Reports describe weight changes, training and estimated fitness. Without controlled comparisons or verified product contents, these cannot establish what the compound caused. A watch estimate of fitness is not a clinical exercise test.
Doses are still experimental
The named online amount is included to explain the discussion, not to establish a human regimen. Mouse amounts and injected animal routes do not supply a safe oral human conversion.
Model details: SLU-PP-332 · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 4.8 hours
- Absorption half-life assumed
- 1.2 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (1.2 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Reviewed evidence does not establish the catalog’s 4.8-hour human half-life or bioavailability. No absolute human Cmax was verified.
- Billon et al. 2023: synthetic ERR agonist and exercise response
Primary abstract identifies in-vitro and mouse experiments; its adequate tool PK is not human clinical PK.
slu-pp-332-relative-timing-2026-10 · version 1
Common questions
Is SLU-PP-332 a peptide?
No. It is a small-molecule research chemical sold alongside peptides.
Does it replace cardio?
No human clinical evidence cited here establishes that. Mouse metabolic effects are not the full benefits of exercise.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- Human benefit remains uncertain.
- Training replacement?
- “Exercise mimetic” describes selected biological effects.
- 1. Billon et al. 2023 — SLU-PP-332 exercise-response experiments
Synthetic ERRα/β/γ agonist; muscle-cell and mouse endurance experiments.
- 2. Billon et al. 2024 — metabolic-syndrome mouse models
Obese mouse energy-expenditure, fatty-acid oxidation and fat-mass findings.
- 3. Avliyakulov and Sobolevsky 2026 — in-vitro metabolites
Pooled human liver S9 fractions and analytical metabolite identification; not dosing volunteers or a human half-life study.
- 4. Billon et al. 2023: synthetic ERR agonist and exercise response
Primary abstract identifies in-vitro and mouse experiments; its adequate tool PK is not human clinical PK.
Related compounds and examples
Related compounds
AICAR
AICAR for endurance: where the exercise-pill claim comes from, reported amounts and comparison with Cardarine.
5-Amino-1MQ
5-Amino-1MQ for fat loss: capsule-dose claims, animal findings and what remains unknown for people.
ACE-031
ACE-031 muscle-growth research: trial doses, myostatin claims and why bigger muscle measures are not enough.